表皮生长因子受体
酪氨酸激酶
表皮生长因子受体抑制剂
酪氨酸激酶抑制剂
癌症研究
突变
医学
药理学
生物
受体
内科学
癌症
遗传学
基因
作者
Weiyan Cheng,Jianhua Zhou,Xin Tian,Xiaojian Zhang
标识
DOI:10.2174/0929867323666160510123604
摘要
Epidermal growth factor receptor (EGFR) is one of the most important targets in anticancer therapy. Till date, a large number of first and second generation EGFR tyrosine kinase inhibitors (TKIs) have been marketed or advanced into clinical studies. However, the occurrence of TKI-resistant mutations has led to the loss of efficacy of these inhibitors. In the purpose of overcoming resistant mutations and reducing side effects, lots of third generation EGFR inhibitors are explored with promising potencies against EGFR mutations while sparing wild-type EGFR. This review outlines the current landscape of the development of third generation EGFR inhibitors, mainly focusing on the biological properties, clinical status and structure-activity relationships. Keywords: Anticancer, Clinical, EGFR, Mutation, Small molecule inhibitor, Third generation.
科研通智能强力驱动
Strongly Powered by AbleSci AI